Fibromyalgia

Fibromyalgia poses challenges extending beyond physical symptoms due to societal misconceptions and inadequate understanding. Clinicians emphasize the importance of addressing mental health, engaging patients actively, and creating supportive environments to improve the wellbeing of these patients.

Patients with fibromyalgia have poorer accuracy for divided attention, mediated by sleep disturbance, according to a new study.

The rheumatology month in review highlights the challenges of fibromyalgia management and uncovers compelling associations regarding rheumatic disease and comorbidities.

Lora Black, PhD, sheds light on the importance of patient-centered education and comprehensive care in fibromyalgia.

Findings shed light on the potential significance of recognizing and managing type D personality traits in the context of fibromyalgia care.

Thematic analysis revealed common themes, including uncertainty about the cause of fibromyalgia, feelings of invisibility, confusion about symptoms and flares, and a strong desire for more accessible treatment information.

Only 10% of providers surveyed follow the American College of Rheumatology criteria for fibromyalgia.

Results indicate the potential relevance of pressure pain thresholds for understanding the mechanisms that contribute to pain in fibromyalgia.

The rheumatology month in review highlights fibromyalgia complexities, lupus advancements, and dietary links to gout for improved management.

Among the fibromyalgia studies conducted in the US and Canada over the past 22 years, 90% of participants identified as White.

Philip J. Mease, MD, highlights the potential of blood biomarkers to assist with diagnosing fibromyalgia, as well as other imaging modalities.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

An expert rheumatologist reviews the efficacy and safety of the 3 FDA-approved therapies for treating fibromyalgia—pregabalin, duloxetine, and milnacipran.

Philip J. Mease, MD, comments on the importance of education about fibromyalgia, especially regarding the stigma and the psychological impact of the disease.

Philip J. Mease, MD, provides an overview of fibromyalgia as a primary disorder of central pain processing and modulation.

Dr Daniel J. Clauw shares clinical pearls for the treatment of patients with fibromyalgia and comments on future developments in the pipeline for disease management.

Daniel J. Clauw, MD, shares his approach to selecting FDA approved therapeutic agents for fibromyalgia treatment and his clinical treatment strategy when first-line pharmacological therapy fails.

Approximately one third of patients with temporomandibular disorders had comorbid fibromyalgia.

Results of a database search reveal the management of pain symptoms remains a continued source of frustration and an unmet need for patients with fibromyalgia.

In the November 2023 rheumatology month in review, our editorial team highlights ACR conference coverage, the latest updates in fibromyalgia, and advancements in patient care.

At 12 weeks, significantly more patients with fibromyalgia receiving the smartphone-based intervention reported clinical improvements compared with the control group.

Findings may be related to a variety of influences including a slower life pace during the pandemic and resilience to prolonged stressors.

In a new study, decreased plasma EGR1 protein levels and patients with fibromyalgia had a statistically significant relationship.